Secondary analysis of a phase 2 RCT in 112 adults with narcolepsy type 1: oveporexton vs placebo over 8 weeks improved attention (PVT lapses -8.6 to -10.8 placebo-adjusted), memory and executive function across most doses.
Secondary analysisn = 112
Lammers et al. Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial